Poseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC Wainwright
MarketBeatHC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Poseida Therapeutics in a report on Wednesday.
HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Poseida Therapeutics in a report on Wednesday.